SCHEMBL8976535

SCHEMBL8976535

CN(C)c1ccc2nc[nH]c(=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 6/20 1.00
PARP1 P09874 9/20 0.63
CHEK1 O14757 2/20 0.58
PIM1 P11309 2/20 0.58
AKT1 P31749 1/20 0.58
FLT3 P36888 1/20 0.58
PIM3 Q86V86 1/20 0.58
SLC2A1 P11166 1/20 0.56
PDPK1 O15530 1/20 0.51
CA12 O43570 1/20 0.51
ALOX15 P16050 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CA9 Q16790 1/20 0.51
TNKS2 Q9H2K2 1/20 0.51
IP6K3 Q96PC2 4/20 0.50
IP6K2 Q9UHH9 3/20 0.50
KDM4E B2RXH2 1/20 0.50
RPS6KA3 P51812 1/20 0.50
ACVR1 Q04771 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31020875 1.00 IP6K1 (1.00) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL22533946 0.87 IP6K1 (0.77) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL31236175 0.87 IP6K1 (0.77) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL31236172 0.87 IP6K1 (0.77) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL29605527 0.77 PARP1 (1.00) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL1507614 0.77 PARP1 (1.00) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL8622180 0.77 ACVR1 (0.73) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL30169420 0.76 IP6K1 (0.60) IP6K1PARP1CHEK1PIM1AKT1
SCHEMBL22130605 0.75 IP6K1 (0.60) IP6K1KDM4E
SCHEMBL2191067 0.74 PARP1 (1.00) IP6K1PARP1CHEK1PIM1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018003-B2 Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-06-25 US disclosed
US-20210309616-A1 SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2021-10-07 US disclosed
US-5580870-A ANTICARCINOGENIC AGENTS ZENECA LIMITED (GB) 1996-12-03 US disclosed
EP-0602851-B1 Quinazoline derivatives ZENECA LTD (GB) 1996-10-09 EP disclosed
CN-1094043-A Quinazoline derivant ZENECA LTD (GB) 1994-10-26 CN disclosed
EP-0602851-A1 Quinazoline derivatives ZENECA LIMITED (GB) 1994-06-22 EP disclosed
US-4011323-A ANTIOBESITY AND ANTIDIABETIC SANDOZ, INC. (US) 1977-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018003-B2 Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors MMP9, MMP7, MMP11 IP6K1 2516/4885PARP1 416/4885CHEK1 4124/4885
US-20210309616-A1 SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS MMP2, MMP9, MMP10 IP6K1 3582/4885PARP1 708/4885CHEK1 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.